Table 4.

Multivariable analysis of the association between minimum ALC and BCM (n = 747)

HR (95% CI)
Minimum ALC0.19 (0.11–0.34)
Neoadjuvant/adjuvant chemotherapy use (vs. none)0.54 (0.29–1.01)
Radiotherapy use (vs. none)0.70 (0.46–1.06)
Neighborhood socioeoconomic status (vs. 1 = lowest)0.85 (0.71–1.00)
NH Black (vs. NH white)1.54 (0.66–3.55)
NH Asian (vs. NH white)0.78 (0.42–1.44)
Hispanic (vs. NH white)1.35 (0.71–2.56)
Positive for deleterious mutation in BRCA1/2a (vs. negative/VUS)0.98 (0.36–2.64)
Untested for deleterious mutation in BRCA1/2a (vs. negative/VUS)1.91 (1.01–3.59)
Age at diagnosis (per year)0.99 (0.98–1.01)
Ever neutropenic (ANC <1 K/μL; vs. never neutropenic)1.01 (0.63–1.62)
Stage II (vs. stage I)2.61 (1.37–4.97)
Stage III (vs. stage I)7.59 (3.83–15.04)
Grade 2 (vs. grade 1)2.27 (0.29–17.66)
Grade 3 (vs. grade 1)3.06 (0.41–22.69)
Unknown grade (vs. grade 1)1.08 (0.11–10.65)
  • NOTE: Statistically significant variables are in bold font.

  • aBRCA1/2 contains an additional “untested” category.